(Q37290943)

19 August 2017

1 reference

title

Tumour cell survival signalling by the ERK1/2 pathway (English)

1 reference

19 August 2017

K Balmanno

1

1 reference

PubMed ID

18846109

19 August 2017

S J Cook

series ordinal

2

1 reference

19 August 2017

10 October 2008

1 reference

Cell Death & Differentiation

19 August 2017

1 reference

19 August 2017

16

1 reference

19 August 2017

368-377

1 reference

19 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/cdd.2008.148

19 August 2017

0 references

cites work

Ras signalling and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Analysis of the transcriptional program induced by Raf in epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

The Bcl-2 apoptotic switch in cancer development and therapy

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

FOXOs, cancer and regulation of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Multisite phosphorylation regulates Bim stability and apoptotic activity

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein BimEL.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Regulatory phosphorylation of Bim: sorting out the ERK from the JNK

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Role of Bim in the survival pathway induced by Raf in epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

c-Cbl is not required for ERK1/2-dependent degradation of BimEL.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Rsk1 mediates a MEK-MAP kinase cell survival signal

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

C-RAF activation promotes BAD poly-ubiquitylation and turn-over by the proteasome

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Unique biology of Mcl-1: therapeutic opportunities in cancer

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Drivers and passengers

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

https://api.crossref.org/works/10.1038%2FCDD.2008.148

1 reference

7 January 2021

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Mutant B-RAF mediates resistance to anoikis via Bad and Bim.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Proliferation of cancer cells despite CDK2 inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

MEK kinase activity is not necessary for Raf-1 function

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.148

7 January 2021

Identifiers

DOI

10.1038/CDD.2008.148

1 reference

19 August 2017

1 reference

PubMed ID

18846109